RxDoctor Payments Data

Joanna Potterfield

Family · Leesburg, VANPI 1649855016

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 35 payments — averaging $29.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$247
  • Antares Pharma, Inc.$236
  • Bayer$106
  • Johnson & Johnson$91
  • Teleflex LLC$88
  • Pfizer$79
  • plus $192 from 6 others

What the payments were for

  • Food & beverage$1,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.7$247
Antares Pharma, Inc.6$236
Bayer5$106
Johnson & Johnson3$91
Teleflex LLC3$88
Pfizer3$79
AbbVie2$62
ABC Home Medical Supply, Inc.2$51
Urogen Pharma, Inc.1$26
Tolmar, Inc.1$21
Immunitybio, Inc.1$19
Hollister Incorporated1$14

How this compares

$1,040 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$43,445
Medicare patients
293
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron17$14,893
Estradiol28$1,492
Tamsulosin Hcl53$510
Finasteride13$293
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$252
CefuroximeCefuroxime Axetil21$170
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$102
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$47
Oxycodone Hcl13$45
Ciprofloxacin Hcl11$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$247$14,89317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →